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Abstract: Babesiosis is a disease caused by tickborne hemoprotozoan apicomplexan parasites of the
genus Babesia that negatively impacts public health and food security worldwide. Development of
effective and sustainable vaccines against babesiosis is currently hindered in part by the absence
of definitive host correlates of protection. Despite that, studies in Babesia microti and Babesia bovis,
major causative agents of human and bovine babesiosis, respectively, suggest that early activation of
innate immune responses is crucial for vertebrates to survive acute infection. Trained immunity (TI)
is defined as the development of memory in vertebrate innate immune cells, allowing more efficient
responses to subsequent specific and non-specific challenges. Considering that Mycobacterium bovis
bacillus Calmette-Guerin (BCG), a widely used anti-tuberculosis attenuated vaccine, induces strong
TI pro-inflammatory responses, we hypothesize that BCG TI may protect vertebrates against acute
babesiosis. This premise is supported by early investigations demonstrating that BCG inoculation
protects mice against experimental B. microti infection and recent observations that BCG vaccination
decreases the severity of malaria in children infected with Plasmodium falciparum, a Babesia-related
parasite. We also discuss the potential use of TI in conjunction with recombinant BCG vaccines
expressing Babesia immunogens. In conclusion, by concentrating on human and bovine babesiosis,
herein we intend to raise awareness of BCG TI as a strategy to efficiently control Babesia infection.
Keywords: Mycobacterium bovis bacillus Calmette-Guerin (BCG); trained immunity; recombinant BCG;
Babesia spp.; Babesia bovis; Babesia microti; human babesiosis; bovine babesiosis; anti-Babesia vaccine
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Babesiosis is a tick-borne disease of vertebrates caused by apicomplexan hemoprotozoan parasites of the genus Babesia [1,2]. Babesia parasites have a complex lifecycle that
involves the development of asexual stages in vertebrate hosts and sexual stages in tick
vectors [1,3,4]. In vertebrate hosts, Babesia has evolved to invade and replicate exclusively
inside red blood cells (RBCs) [1]. Since RBCs lack the machinery to process and present
antigens, this strategy provides a relatively safe environment for the parasite to evade the
vertebrate immune system. Considered an emerging disease in humans and an economically important condition for cattle, human and bovine babesiosis can adversely affect
public health and food security, respectively [1–8]. Babesiosis in humans is predominantly

Vaccines 2022, 10, 123. https://doi.org/10.3390/vaccines10010123

https://www.mdpi.com/journal/vaccines

Vaccines 2022, 10, 123

2 of 18

caused by Babesia microti in the USA and Babesia divergens in Europe [9,10]. Clinical signs
of human babesiosis vary from mild flu-like symptoms to severe disease, especially in
immunocompromised individuals, which are characterized by renal failure, acute respiratory distress, and disseminated intravascular coagulations [11]. No vaccines are currently
available to protect humans against babesiosis. Moreover, the emerging situation of the
disease in the USA is worsened by the recent appearance of competent ticks for B. microti
in previously tick-free areas [12–14]. The use of anti-babesial drugs, such as azithromycin
and atovaquone, is the only current option to treat human babesiosis. However, the development of resistance to these therapeutics and the potential transmission of parasites,
especially B. microti, via blood supply are major concerns [9,15,16].
Several Babesia species infect and cause disease in domestic and wild animals [8,17].
In this review, we focus on bovine babesiosis caused by B. bovis and B. bigemina, an economically important disease that affects cattle in tropical and sub-tropical countries [1,3].
Acute babesiosis in immunologically naïve cattle is characterized by high fever and severe
anemia that can progress to either death or asymptomatic persistent infection [1]. The
pathogenesis of acute B. bovis infection is also frequently accompanied by accumulation
of parasite-infected RBCs in the microvasculature of vital organs, including the brain,
resulting in cerebral babesiosis that resembles cerebral malaria in humans [18–20]. Live,
blood- or in vitro culture-based, attenuated vaccines against B. bovis and B. bigemina are
available in some endemic areas; however, these interventions have several constraints
that prevent their widespread use [21–25]. Alternatively, anti-babesial drugs can be used
to control acute bovine babesiosis, but this strategy is expensive and unpractical for large
herds of cattle, in addition to raising concerns for potential development of drug-resistant
parasites and antibiotic residues [26–30].
Development of efficacious and sustainable vaccines against human and bovine
babesiosis is urgently needed; however, critical knowledge gaps remain on the protective immune responses of the vertebrate host to Babesia parasites. Importantly, concerning
bovine babesiosis, young cattle (<1-year old) are resistant to B. bovis and B. bigemina acute
disease and may become chronically asymptomatic reservoirs for parasite transmission [31].
This resistance of calves to acute babesiosis is associated with early activation of proinflammatory innate immune responses and is independent of passive immune maternal
factors [32–37]. Therefore, myeloid innate immune cells, such as monocytes, macrophages,
and dendritic cells (DC), may play a critical role in protection against Babesia. Collectively,
results suggest that a balanced pro-inflammatory innate immune response, combined with
production of nitric oxide (NO), can control parasitemia during acute infection, allowing
the host to develop a protective acquired immune response [36,38–43]. However, definitive
correlates of protection against human and bovine babesiosis remain largely unknown and
represent an important knowledge gap for vaccine development.
Trained immunity (TI) is defined as a reprograming of the vertebrate innate immune
system evoked by certain exogenous or endogenous insults, leading to immunological
memory and more efficient responses to subsequent specific or non-specific challenges [44].
Interestingly, TI involves epigenetic and metabolic modifications of the vertebrate innate
immune myeloid cells, specifically monocytes, macrophages, DC, and neutrophils [44–46].
Furthermore, results show that TI is independent of T and B cell responses [46]. Predictably,
this emerging field of immunology has implications for the development of vaccines and
therapeutics against infectious diseases. Of particular interest is the observation that some
live attenuated vaccines induce TI, making innate immune cells more efficient in responding
to heterologous challenges [44,46–49]. Therefore, this heterologous immunity caused by live
vaccines can be explored to develop novel prophylactic and therapeutic control strategies
against pathogens. Mycobacterium bovis bacillus Calmette-Guerin (BCG) is a live attenuated
vaccine that has been used worldwide for more than 100 years to prevent tuberculosis
(TB) in humans. With a long history of use against TB and excellent safety record, BCG is
currently part of the World Health Organization immunization program [50]. A large body
of recent evidence indicates that BCG induces TI that is characterized by the development of
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circulating monocytes, macrophages, and natural killer (NK) cells with increased capacity
to produce pro-inflammatory cytokines [46,48,51,52]. Initial studies demonstrated that
BCG TI induces cross-protection against Candida albicans and Staphylococcus aureus, among
other unrelated pathogens [46,53]. Subsequent observational studies in children in West
Africa demonstrated that BCG vaccination decreases morbidity due to infections other
than TB, including malaria [54,55]. Very recently, epidemiological studies indicated that
TI induced by BCG could be protective against the development of severe coronavirus
disease 2019 in humans [56,57]. Strikingly, studies performed in the 1970’s showed that
BCG inoculation protects mice against lethal experimental infection with B. microti and
Plasmodium berghei [58,59]. At the time, no immunological mechanism was identified as
responsible for this protective effect of BCG on B. microti and P. berghei, and no further
investigations were reported [60]. Regardless, these results suggest that BCG TI may induce
cross-protection against apicomplexan parasites, including Babesia and Plasmodium species.
Here in this review, we consider the re-emerging importance of BCG within the
novel field of TI in conjunction with the evidence that this attenuated bacillus induces
heterologous cross-protection, specifically against apicomplexan parasites. Our goal is to
raise awareness of BCG TI in the context of Babesia infection and discuss the prospective
application of BCG to train immune cells to control human and bovine babesiosis. We also
discuss the possibility of using TI in conjunction with recombinant BCG (rBCG) vaccines
expressing Babesia immunogens to generate acquired immunity as well.
2. Human and Bovine Babesiosis
Human babesiosis is an acute and persistent disease caused primarily by B. microti and
B. divergens; however, emerging cases of infections with B. duncani and B. divergens-like parasites have also been reported in the USA [7,9,11,16,61,62]. Humans are accidental hosts of
B. microti and most cases occur from late spring to early autumn when humans are in closer
contact with tick vectors and definitive mammalian hosts, such as rodents and deer [16,63].
Worrisomely, B. microti, and potentially other Babesia species, can be transmitted to humans via blood transfusion, making it an important emerging threat to the blood supply
worldwide [9,64,65]. No vaccine is currently available to protect humans against babesiosis,
and the recent emergence in the USA of B. microti infections that are resistant to available
therapeutics has raised serious concerns about the availability of treatments [66,67]. In
addition, splenectomized and/or immunosuppressed individuals are more susceptible to
B. microti infection that can progress into a life-threatening condition [11]. B. microti is a
sensu lato species which is transstadially transmitted by tick vectors, and this biological
characteristic needs to be considered for the development of efficient strategies to control
the parasite. Altogether, these aspects demonstrate that a comprehensive assessment of the
impact of human babesiosis on public health and the development of measures to control
the disease are urgently needed.
Bovine babesiosis imposes draconian economic losses on cattle production in tropical and subtropical countries and represents a serious threat to food security worldwide [3,25,68,69]. Notably, B. bovis and B. bigemina are the most prevalent etiological agents
of bovine babesiosis; however, the disease in bovids can also be caused by B. divergens,
B. occultans, B. major, B. orientalis, and B. ovata, among other species [3,65,66]. Live-attenuated
B. bovis and B. bigemina vaccines have been successfully used to control the devastating
effects of acute disease in some endemic areas. Regardless of their relative efficacy, the
B. bovis and B. bigemina attenuated live vaccines have several constraints that preclude
their widespread use, especially for eradication programs in endemic areas and control
strategies in non-endemic at-risk regions. Among the limitations of the live vaccines, there
are the reliance on cattle for vaccine production, risk of co-transmission of unrelated blood
pathogens, potential variation among vaccine batches, possibility of reversion to virulence,
need for a cold chain for vaccine distribution, and establishment of persistent infection in
vaccinated animals that can serve as reservoirs for parasite transmission [1,21,23,24]. These
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restrictions clearly demonstrate that improved, sustainable, and more efficient vaccines are
needed to control bovine babesiosis.
Development of anti-babesial vaccines has been hampered by knowledge gaps in the
identification of protective parasite antigens and the absence of definitive correlates of protection against the disease in vertebrate hosts. Babesia genome sequencing, combined with
the development of transfection and gene editing methods, have advanced the knowledge
of the parasites’ biology and its lifecycle. Despite the progress, critical gaps remain in our
understanding of the parasite-host-tick interactions, which in part explains the current
absence of effective subunit vaccines against babesiosis [70–78]. Furthermore, definitive
correlates of protection against Babesia infection are unavailable and represent a major impediment for the development of efficient control strategies. Thus, a better understanding
of parasite biology and the immunological mechanisms, especially the innate immune
responses associated with protection, is a critical step toward the development of effective
anti-babesial vaccines.
3. Immune Responses to Babesia spp.
Most of our current knowledge of immune responses to Babesia parasites has emerged
from research in B. bovis and B. microti using cattle and mouse models, respectively. Collectively, these studies indicate that early activation of innate immunity is a key component
for the vertebrate host to control parasitemia and survive acute infection [34,42,43,79–81].
Expression of pro-inflammatory cytokines, such as IL-12 and IFNγ, early during acute
infection and consequent delay in the production of the regulatory cytokine IL-10, is crucial
to control parasitemia and develop protective acquired responses. Pro-inflammatory cytokines can act in an autocrine or paracrine manner to activate monocytes and macrophages
to produce NO, which has been shown to be babesicidal [38,40,43,82]. It is, therefore, predicted that control of parasitemia during the early pre-clinical stage of the infection is
mediated by myeloid innate immune cells [39,42,83]. It has also been shown that natural
killer (NK) cells are a potential source of IFNγ early during acute Babesia infection, which
may play a role in fine-tuning the profile of cytokine expression and boost activation of
monocytes, macrophages, and DC [34,36,37,80].
Despite the importance of innate immunity, development of acquired immune responses, such as activation of CD4+ T lymphocytes and B cells in the spleen, are necessary
for the resolution of acute clinical disease and transition into chronic asymptomatic infection. Activation of acquired immune responses during Babesia infection leads to the
production of IFNγ, mainly by CD4+ T lymphocytes, which activates additional myeloid
and lymphoid immune cells [84,85]. Collectively, this process helps the resolution of acute
infection during late clinical stages of disease and promotes the development of protective and memory responses [83,86]. The role played by humoral immunity in limiting
acute bovine babesiosis remains controversial, considering that some young cattle resolve
acute infection in the absence of antibodies. However, it is possible that humoral immune responses, combined with cellular acquired responses, may play a role in controlling
parasitemia during the chronic asymptomatic phase of the infection [72,87,88].
Historically, it has been demonstrated that young cattle (<1-year old) survive acute
disease caused by virulent B. bovis and B. bigemina strains, and may develop persistent
infection, becoming resistant to re-infections during adulthood and reservoirs for parasite
transmission [31]. In contrast, susceptible adult bovines (>1-year old) succumb to acute
disease approximately 15 to 20 days after infection [32,33]. This scenario presents a unique
opportunity to study immune responses in resistant calves and compare them with those in
adult susceptible animals. Importantly, it is reasonable to consider that infection of young
cattle and development of persistent asymptomatic disease favor both the parasite and
vertebrate host. This situation is particularly observed for bovine babesiosis in endemically stable regions in tropical and subtropical areas worldwide [89–92]. Interestingly,
splenectomy abrogates the resistance of young cattle to Babesia infection and aggravates
the condition of adult animals, indicating that the spleen plays a crucial role in protec-
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tion [93–95]. In fact, a specific splenic CD13+ DC population was identified in bovine as a
potential source of IL-12 after exposure to B. bovis [36].
In a nutshell, the available data support the premise that protection against acute
babesiosis is associated with early activation of pro-inflammatory innate immune responses.
As the vertebrate host survives the acute phase of the disease, it is likely that acquired
immune responses, primarily driven by CD4+ T cells, are essential for establishing persistent infection in clinically healthy individuals. Despite the progress in our understanding
of Babesia immunology, specific immunological biomarkers of protection remain largely
unknown. Considering that innate immunity is essential for controlling parasitemia during
acute infection and survival of the vertebrate host, efficient activation of myeloid innate
immune cells, perhaps via TI, emerges as a reasonable and possible approach to control
acute babesiosis.
4. Mycobacterium bovis BCG
BCG is a strain of Mycobacterium bovis that was empirically attenuated through several
in vitro passages between 1908 and 1921 at the Pasteur Institute of Lille, France [96]. Subsequent evaluation of BCG in animal models demonstrated its infectivity yet significant
attenuation. In the late 1920’s, BCG was recommended by the League of Nations as the official vaccine against human TB, and since then, it remains the only commercially available
vaccine against the disease. BCG is currently the world’s most widely used vaccine and has
been administered safely to more than three billion people. BCG offers unique advantages
as a live attenuated vaccine: it is unaffected by maternal antibodies and therefore, it can
be given at any time after birth; BCG is stable and safe; it is usually given as a single dose
eliciting a long-lasting immunity; it can be administrated parenterally or orally; and it is
inexpensive to produce when compared to other live vaccines. In addition, the strong
adjuvanticity of BCG makes it an attractive vector for the development of recombinant vaccines against infectious diseases of vertebrates [97–103]. Despite the advantages and strong
record of safety, the efficacy of BCG as an anti-TB vaccine remains controversial [104–107].
Recent analysis of the BCG genome demonstrated several deletions and rearrangements that likely happened during its continuous in vitro cultivation that led to attenuation [108–111]. One such deletion involved the loss of the region of difference 1 (RD1),
which encodes for the 6-KDa early secretory antigenic target (ESAT-6) and the culture filtrate
protein-10 kDa (CFP-10), among other genes [112,113]. As a result of the absence of RD1,
after phagocytosis, BCG remains in the phagosome, in contrast to virulent M. bovis, Mycobacterium leprae and Mycobacterium tuberculosis that escape into the host cell cytosol [114].
This characteristic has implications for the establishment of persistent infection by BCG
after vaccination, considering that some bacilli are killed inside the cell phagosomes [115].
Nevertheless, one unquestionable trait of BCG vaccination is the strong activation of proinflammatory innate immune responses, which leads to the development of a T helper
type 1 (TH1)-like acquired immune response [116–119]. Moreover, once BCG was developed at the Pasteur Institute, visiting scientists took stocks to their respective countries
of origin at various times, giving rise to several daughter strains or substrains, such as
Birkhang, China, Connaught, Copenhagen, Denmark, Frappier, Glaxo, Japan, Mareau,
Mexico, Pasteur, Phipps, Prague, Russia, Sweden, and Tice [120]. This led to different
passage histories and the inevitable in vitro evolution of diverse strain genotypes and
phenotypes. For instance, the current BCG Pasteur differs from the original Pasteur strain
by polymorphisms and deletions. BCG strains are used both as a vaccine to prevent TB
and as an immunotherapy of bladder cancer [57,121]. In addition, there is active research
on the use of BCG to treat other cancers and non-infectious diseases, such as autoimmune
disorders and type I diabetes [122]. Several studies have addressed how genetic differences
among BCG substrains may be reflected in alterations of immunogenicity and protection
against TB and non-mycobacterial diseases. However, reaching definitive conclusions has
not yet been possible, due to confounding effects. Thus, although the substrain selection
is an important consideration in any potential use of BCG TI, definitive guidelines have
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not been established. In the USA, two formulations of the strain Tice (developed by the
University of Illinois from a strain originated at the Pasteur Institute) are approved against
TB: BCG Vaccine U.S.P. for percutaneous use and BCG Live (TICER BCG) for intravesical
use as described in the corresponding package inserts.
Following inoculation, BCG pathogen-associated molecular patterns (PAMPs), such
as peptidoglycan, arabinogalactan, and mycolic acids located at the bacterial cell wall,
are recognized by pattern recognition receptors (PRRs) of monocytes, macrophages, and
DC. Among the surface PRRs that recognize BCG PAMPs are toll-like receptors (TLR) 2,
TLR4, and mannose receptors [123]. In addition, complement receptor (CR) 3 and CR4
opsonize BCG, favoring recognition and phagocytosis of the bacillus by the innate immune
cells. After phagocytosis, BCG PAMPs are also recognized by cytosol receptors, such
as nucleotide-binding and oligomerization domain (NOD)-like receptors (NLRs), and
C-type lectins, retinoic acid-inducible gene I (RIG-I)-like receptors. Combined, these
events lead to activation of myeloid cells, which is characterized by up-regulation of costimulatory surface molecules CD40, CD80, and CD86 [124–126]. Also, BCG-activated
innate immune cells up regulate the expression of pro-inflammatory cytokines, mainly IL12, IL-1β, TNFα, IL-6, and IL-8, and migrate to regional lymphoid organs where they act as
antigen-presenting cells to lymphocytes, initiating the acquired immune responses [125,127].
As a result, CD4+ and CD8+ T lymphocytes produce large amounts of IFNγ, which in
turn, induces further activation of myeloid cells to up regulate the expression of proinflammatory cytokines.
In addition to eliciting pro-inflammatory immune responses, BCG also reprograms
the host metabolic pathways, which has a profound impact on how individuals respond to
related and non-related pathogens. It has been demonstrated that BCG switches the cell
metabolism from oxidative phosphorylation to glycolysis, therefore affecting the development of protective immunity [128]. The combined effects of BCG vaccination on immune
responses and metabolism may mechanistically explain the heterologous protection induced by the bacillus and its TI characteristic.
5. BCG and Trained Immunity
Recent studies have demonstrated that certain live attenuated vaccines induce TI, defined
as the development of immunological memory in classical innate immune cells [44,129–131].
However, TI differs from innate immunity as it is expressed in response to a secondary
infection following primary infection by an unrelated pathogen or vaccination with liveattenuated vaccines. This paradigm shift sheds light on potential mechanisms for the
observed effects that live vaccines have on unrelated pathogens. Of particular interest
is the fact that BCG induces TI; however, this observation has also been reported after
inoculation with other live vaccines, such as those against measles, smallpox, and the
Sabin polio vaccine [47,132]. An important body of work indicates that BCG induces TI
in myeloid innate immune cells by epigenetic mechanisms involving DNA methylation,
histone modification, and expression of non-coding RNA [53,132]. In addition, BCG
induces metabolic changes in immune and non-immune cells of vaccinated hosts, which
may have an impact on how the cells respond to pathogens [44,51,129,130,133]. Initial
studies showed that BCG TI was responsible for heterologous protection against Candida
albicans and Staphylococcus aureus [46]. The beneficial non-specific effects of BCG TI were
also demonstrated by a significant reduction of newborn deaths due to mycobacterial
unrelated infectious diseases in BCG vaccinated populations in West Africa [54].
After BCG vaccination, innate immune cells are activated by bacterial cell wall components, and this cell-pathogen recognition mechanism is behind the well-described ability
of the bacillus to serve as an immune adjuvant [124,125]. BCG-activated monocytes,
macrophages, and DC produce pro-inflammatory cytokines, which can have an effect
against unrelated pathogens [48,51]. In addition, cells activated by BCG develop a TI
profile, which in monocytes is characterized by histone modifications with methylation of
lysine at positions 4 and 9 in the histone 3, H3K4me3 and H3K9me3, respectively, within the
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promoters of the TNFα, IL-6, TLR4, and IL-1β genes [128]. These alterations lead to up regulation of these specific genes and development of an efficient pro-inflammatory response
upon subsequent encounter with related or unrelated pathogens [46,51]. Interestingly, it
has been shown that BCG vaccination can also induce epigenetic changes in bone marrow
progenitor myeloid cells, generating myelopoiesis and trained cell populations highly
equipped to respond to a variety of pathogens [134,135]. This mechanistically explains how
BCG TI can potentially have a long-lasting effect regardless the short life of monocytes,
macrophages, DC, and neutrophils. In fact, BCG TI has been shown to have a long-term
effect on innate immune cells that ultimately drives efficient TH1 and T helper 17 (TH17)
acquired responses [46,136].
BCG vaccination was shown to provide protection against bovine tuberculosis in
cattle [137]. However, the purified protein derivative (PPD) skin assay is considered
the gold standard diagnostic test for TB in vertebrates, including humans and livestock.
Unfortunately, BCG vaccination usually induces positive PPD results. Several studies
have been performed to overcome this limitation. Some approaches focused on the use of
DIVA (differentiating infected from vaccinated animals) diagnosis. Tests with significant
sensitivity and specificity have been developed based on antigens or peptide mixtures
that are not present (ESAT-6, CFP10) or not secreted by BCG (Rv3615c) that can be used
both as IFNγ blood or skin tests [138]. Moreover, the utility of these tests was evaluated in
field studies with promising results in low- and middle-income countries [139,140]. Other
investigations attempted the development of BCG strains that are unable to induce PPD
positive results. One study showed that a BCG leuD auxotrophic mutant was able to protect
guinea pigs without eliciting a PPD response [141]. However, the corresponding M. bovis
leuD mutant, while providing protection in cattle, still elicited a strong PPD response [142].
Another approach combined both DIVA antigens with the development of a BCG triple
deletion mutant that ablated five BCG genes (3043, 2895, 2897, 3679, and 3680). The
antigens encoded by the deleted genes were then used in cocktails to demonstrate their
DIVA potential in guinea pigs [143]. Although the mutants described herein were marked
with drug-resistant determinants, several technologies have been developed to generate
multiple unmarked mutants [144,145]. The challenge remains in optimizing protection
while maintaining DIVA capabilities in cattle. Nonetheless, these developments open
several opportunities for the widespread use of BCG TI to induce heterologous protection
against pathogens, without interfering with TB control programs.
Considering the resurgence of BCG as an TI inducer and the crucial role that innate
immunity plays in initiating and driving acquired protective immune responses, the impact
of BCG TI needs to be further investigated in the context of relevant infectious diseases
of vertebrates. Therefore, the use of BCG TI to help protect against B. microti and B. bovis
infections, and other apicomplexans, emerges as a rationale and doable option, especially
considering the current absence of efficacious and sustainable approaches to control human
and bovine babesiosis.
6. BCG Trained Immunity in the Context of Babesia Infection
Considering the ability of BCG to train innate immune cells and the importance
that the innate immune system has in protecting vertebrates against Babesia infection, we
revisited seminal studies performed in the 1970’s which demonstrated that BCG inoculation
protected mice against lethal challenge with B. microti and P. berghei. [58,59]. Interestingly,
these studies demonstrated that the BCG-mediated protection against B. microti resulted
in intracellular death of the parasite, which was not mediated by antibodies or increased
phagocytic activity of monocytes/macrophages. At the time, no mechanistic explanation
was available for the observed protection of BCG against B. microti. Here we propose a
possible model to reinterpret those early observations considering the novel discoveries
indicating that BCG TI induces epigenetic and metabolic changes that may control infections
with apicomplexan parasites.
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BCG vaccination induces a massive and rapid elicitation of the innate immune responses
characterized by activation of monocytes, macrophages, DC, and neutrophils [118,124–126].
Studies in humans and mice have also shown that BCG inoculation induces NK cells to
secrete IFNγ, which ultimately enhances the activation of myeloid innate immune cell
populations [146,147]. BCG activation of the innate immune cells drives primarily the
development of a pro-inflammatory TH1 acquired immune response, with marked production of IFNγ primarily by CD4+ T cells and clonal expansion of B cells [116,117,119].
Activation of innate immunity and development of a TH1 profile induced by BCG vaccination markedly modulates the entire immune responses of vertebrates and can affect
both related and unrelated pathogens. Regarding apicomplexan parasite infections, it was
shown that BCG inoculation can prevent experimental cerebral malaria in mice [148]. In
addition, BCG vaccination modulates clinical, immunological, and parasitological features,
favoring the control of malaria infection in humans [55]. One study demonstrated that BCG
protected mice against P. yoelii infection by shifting the immune response toward TH1 type
and induction of protective IgG2a [149]. Collectively, it is likely that the development of
TI following BCG vaccination is potentially the mechanism behind the unspecific effect of
this attenuated bacillus against unrelated pathogens, including apicomplexan parasites.
This hypothesis needs to be further investigated considering the recent knowledge of BCG
TI and its potential implication in controlling human and bovine babesiosis. Therefore,
we postulate that epigenetic reprograming caused by BCG would allow myeloid cells to
respond faster and more efficiently to Babesia infection, which in turn, could protect against
the acute phase of the disease. Once activated, BCG TI mechanisms could help the innate
immunity control parasitemia during acute infection, buying time for the vertebrate host
to develop a protective acquired immune response. This hypothesis is supported by the
studies of B. microti and P. berghei in the mouse model [58,59]. The premise is also reinforced
by previous observations in the cattle-B. bovis model indicating that early activation of
innate immune responses, with consequent production of pro-inflammatory cytokines, is
essential for the host to survive acute infection [34,42,43,83]. Therefore, the innate immune
responses elicited by BCG vaccination and subsequent elicitation of TI are the same ones
required for protection against Babesia acute infection. In Figure 1 we propose a model of
BCG TI and its potential implication on Babesia infection. Table 1 summarizes the BCG TI
and its potential effects on Babesia.
Table 1. BCG trained immunity and its potential effects on Babesia infection.
BCG Trained Immunity

Potential Effect on Babesia Infection

Activation of myeloid innate immune cells to
up regulate pro-inflammatory cytokines and
inflammasome pathways [44,46,51,130,131].

Autocrine and paracrine activation of innate
immune cells by pro-inflammatory cytokines
that can control parasitemia early during
Babesia acute infection [39,40,42,43,83].

Priming myeloid innate immune cells to
produce reactive nitrogen species
(RNS) [150,151].

Induction of babesicidal RNS, including
NO [39–41].

BCG vaccination switches the metabolisms of
immune and non-immune host cells from
oxidative phosphorylation to glycolysis [133].

Metabolic alterations may affect the
development of protective immunity against
apicomplexan parasites [152]; for instance,
more availability of arginine to innate immune
cells and RBCs may be associated with NO
production and control of Babesia parasitemia,
as demonstrated in Plasmodium [153,154].

A recent study demonstrated that BCG aerosol vaccination induces the development
of a TI phenotype in bovine monocytes [52]. Results from this study showed a significant increase in the expression of pro-inflammatory cytokines and metabolic changes in
monocytes from BCG-exposed cattle compared to cells from control animals. In addition,
data indicate that BCG TI induced functional changes in bovine monocytes, which were
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characterized by increased transcription of pro-inflammatory cytokines upon stimulation
with TLR agonists [52]. Collectively, the B. bovis-cattle model may be uniquely suited to investigate the usefulness of BCG TI against relevant cattle diseases, such as bovine babesiosis.
In this context, it remains to be determined if BCG TI can control Babesia parasitemia during
acute infection in cattle, allowing the host to mount protective acquired immune responses.
Also, studies are needed to investigate phenotypic and epigenetic differences in myeloid
cells between BCG-vaccinated and naïve individuals and the implications for susceptibility
Vaccines 2022, 9, x FOR PEER REVIEW
9 of 18
and resistance to acute babesiosis. These investigations may reveal novel innate immune
correlates of protection that can be exploited to design effective anti-babesial vaccines.

Figure 1. Trained immunity (TI) induced by Mycobacterium bovis BCG and its implication on Babesia
infection. (a) Upon inoculation, BCG is phagocytosed by (b) myeloid cells, primarily monocytes,
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toolbox provides us with ample opportunities to construct rBCG strains that could first
induce TI against Babesia at early-times post infection followed by the induction of specific
protective antigens that could induce acquired immunity at later times following the parasite infection. In fact, the ability of BCG to deliver the B. bovis rhoptry associated antigen 1
(RAP-1) was successfully evaluated in mice, supporting the hypothesis that rBCG can be
employed as a component of anti-babesial vaccines [167]. Considering that the referred
study was performed in mice, it remains to be determined if rBCG expressing babesial
antigens can protect cattle against babesiosis.
8. Conclusions
In a seminal paper published in 1933 [96], Dr. Albert Calmette asked, “Does the
harboring of BCG confer on the organism a special aptitude to resist those other infections
which are so frequent in young children?” Dr. Calmette’s question was raised in relation
to the potential effects of BCG vaccination on protecting infants from non-tuberculosis
infections. Today, we can certainly answer the question in an affirmative way considering
what we now understand of the TI mechanisms induced by BCG vaccination. In this
regard, it becomes clear that understanding the specific immune pathways and epigenetic
signatures of BCG TI is essential to develop novel therapeutic control strategies against
relevant infectious diseases of vertebrates. We predict that BCG TI and rBCG could be
new and efficient approaches to induce protection against acute babesiosis in humans
and cattle. This strategy can be used as a solo method to control acute infection and
prevent deaths, either in combination with specific anti-babesial vaccines or using a specific
rBCG as indicated above, to also prevent the establishment of persistent infection. This
single or dual strategy could potentially decrease parasite load in the vertebrate reservoir
host, diminishing the potential for parasite transmission and help control the disease.
Additionally, by better preparing the vertebrate innate immunity to control babesiosis, BCG
TI can also play an auxiliary role in programs to eradicate the disease. For instance, BCG
can be used in conjunction with anti-babesial and/or anti-tick vaccines, or rBCG carrying
babesial antigens, to prevent the development of blood and sexual stages of the parasite.
The success of this strategy will simultaneously need the development of approaches
to decrease and/or eliminate the parasite in tick vectors, such as transmission-blocking
vaccines. In conclusion, we propose the use of the B. microti-mouse and B. bovis-cattle
models to address pertinent questions regarding the effect of BCG TI and rBCG on human
and bovine babesiosis, respectively. For instance, if BCG TI is efficient in controlling
acute Babesia infection, what is the immunological mechanism(s) involved in protection?
What is the duration of the effect? Do individuals vaccinated with BCG and subsequently
infected with Babesia become persistently infected with the parasite? If so, can they serve as
reservoirs for parasite tick acquisition and transmission? Is rBCG expressing a specific set
of cytokines more efficient than wild type BCG in training the vertebrate innate responses
against Babesia? What is the BCG-mediated epigenetic landscape associated with protection
against acute babesiosis? Can different routes of BCG delivery enhance protection against
Babesia parasites? Can BCG TI help overcome the difficulties of achieving heterologous
protection with anti-babesial subunit and attenuated vaccines? Addressing these questions
about BCG TI in the context of Babesia infection will certainly open new opportunities for the
development of sustainable and efficient strategies to control human and bovine babesiosis
and provide crucial leads to control other important human and veterinary diseases.
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